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Background: While metastasis ranks among the most lethal of all cancer-associated processes, on the molecular
level, it remains one of the least well understood. One model that has gained credibility in recent years is that
metastasizing cells at least partially recapitulate the developmental process of epithelial-to-mesenchymal transition
(EMT) in their transit from primary to metastatic sites. While experimentally supported by cell culture and animal
model studies, the lack of unambiguous confirmatory evidence in cancer patients has led to persistent challenges
to the model’s relevance in humans.
Methods: Gene expression profiling (Affymetrix, U133) was carried out on 14 matched sets of primary (ovary) and
metastatic (omentum) ovarian cancer (serous adenocarcinoma) patient samples. Hierarchical clustering and
functional pathway algorithms were used in the data analysis.
Results: While histological examination reveled no morphological distinction between the matched sets of primary
and metastatic samples, gene expression profiling clearly distinguished two classes of metastatic samples. One class
displayed expression patterns statistically indistinguishable from primary samples isolated from the same patients
while a second class displayed expression patterns significantly different from primary samples. Further analyses
focusing on genes previously associated with EMT clearly distinguished the primary from metastatic samples in all
but one patient.
Conclusion: Our results are consistent with a role of EMT in most if not all ovarian cancer metastases and
demonstrate that identical morphologies between primary and metastatic cancer samples is insufficient evidence
to negate a role of EMT in the metastatic process.
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Epithelial-to-mesenchymal transition (EMT) is a process
by which epithelial cells acquire mesenchymal cell charac-
teristics including reduced cell adhesiveness and increased
cell motility [1]. The process is an essential component of
embryonic development and is known to be both transient
and reversible (mesenchymal-to-epithelial transition or* Correspondence: john.mcdonald@biology.gatech.edu
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reproduction in any medium, provided the orMET). Initial observations that many characteristics of
cancer metastasis appear to be recapitulations of key fea-
tures of EMT/MET, led to the hypothesis that similar, if
not identical, molecular mechanisms may be involved
[2-4]. While numerous subsequent studies conducted in
cell lines and animal models have supported this hypoth-
esis (e.g., [5-8]), the lack of unambiguous evidence from
studies involving human tumor samples has resulted in
skepticism [9,10]. One persistent objection to the model is
the fact that careful morphological examinations of hu-
man metastases have never uncovered the existence of
cancer mesenchymal-like cells [9]. Indeed, while it is clear
that cancer metastasis must involve detachment of cancerThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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well be attributed to mutation(s) and/or aberrant gene ex-
pression patterns in one or a few genes and not necessarily
reflect involvement of a more coordinated process such as
EMT [9]. Although these alternative possibilities are not
mutually exclusive, a clarification of the molecular mech-
anism(s) underlying metastasis is critical because it could
have significant ramifications on future directions inFigure 1 Unsupervised classification of differentially expressed genes
of patients. (a) Unsupervised hierarchical clustering performed on 3,365 u
expression variation across all samples (SD≥ 0.8). Primary and metastatic sa
another (Group1) while primary and metastatic samples from 2 patients (48
Unsupervised hierarchical clustering of the same genes/probe sets in (a) ac
samples cluster most closely with their matched M samples for all patients
in (a) across primary (P) and metastatic (M) samples of Group 2 patients. Th
same patient.the development of diagnostic tests and potential anti-
metastatic drugs [11].
Ovarian cancer is the most malignant of all gy-
necological cancers and is responsible for over 14,000
deaths per year in the United States alone [12]. Because
ovarian cancer is often asymptomatic early in its pro-
gression (Stages I/II), the disease is not typically diag-
nosed until later stages (Stages III/IV) when the cancerbetween primary and metastatic samples identifies two groups
nique, annotated genes (4,389 probe sets) displaying significant
mples from 5 patients (617, 542, 551, 620, 588) clustered closely to one
9, 528) clustered distantly from one another (Group 2); (b)
ross primary (P) and metastatic (M) samples of Group 1 patients. All P
; (c) Unsupervised hierarchical clustering of the same genes/probe sets
e P samples do not cluster with the matched M samples of the
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< 30%) [12]. Ovarian cancer metastasis is primarily due
to the exfoliation of malignant cells or cell aggregates
from the primary tumor into the abdominal cavity and
their subsequent spread and attachment to visceral and
parietal peritoneal surfaces of abdominal organs such as
the omentum. This mechanism of intra-abdominal meta-
static spread allows for the capture and molecular com-
parison of primary and metastatic cancer cells isolated
from the same patient, providing a favorable opportunity
to evaluate the potential role of epithelial-to-mesenchymal
transition (EMT) in the metastatic process.Table 1 The 20 most significantly enriched pathways
between all primary and metastatic samples.
Functional pathways pValue
1 Cytoskeleton remodeling_TGF, WNT and
cytoskeletal remodeling
1.53E-13
2 Cell adhesion_ECM remodeling 1.03E-11
3 Cytoskeleton remodeling_Cytoskeleton remodeling 7.54E-11
4 Development_Regulation of epithelial-to
-mesenchymal transition (EMT)
9.43E-11
5 Cell adhesion_Chemokines and adhesion 1.75E-10
6 Oxidative phosphorylation 1.99E-10
7 Development_TGF-beta-dependent induction of
EMT via MAPK
2.05E-09
8 DNA damage_Brca1 as a transcription regulator 3.36E-09
9 Cytoskeleton remodeling_Reverse signaling by
ephrin B
6.64E-09
10 LRRK2 in neurons in Parkinson’s disease 2.32E-08
11 Apoptosis and survival_BAD phosphorylation 5.22E-08
12 Development_TGF-beta-dependent induction of
EMT via RhoA, PI3K and ILK
5.30E-08
13 Cytoskeleton remodeling_Role of PKA in
cytoskeleton reorganisation
1.30E-07
14 Transcription_Androgen Receptor nuclear signaling 2.02E-07Methods
Tissue collection
Tissues were collected at Northside Hospital (Atlanta,
GA) under appropriate Institutional Review Board pro-
tocols (H09227). Following resection, tissues were histo-
logically examined samples placed in cryotubes and
immediately (<1 minute) frozen in liquid nitrogen. Sam-
ples were transported on dry ice to Georgia Institute of
Technology (Atlanta, GA), and stored at −80°C. After
examination and verification by a pathologist, tissues
were embedded in cryomatrix (Shandon). The clinical
information of the primary and metastatic cancer tissues
from the seven patients is found in Additional file 1.
For each of the primary and metastatic (omental) tis-
sue samples, 7 μm frozen sections were cut and attached
to uncharged microscope slides. Immediately following
dehydration and staining (HistoGene, LCM Frozen Sec-
tion Staining Kit, Arcturus. Life Technologies), slides
were processed in an Autopix (Arcturus) instrument for
laser capture microdissection (LCM). CapSure Macro-
LCM Caps (Arcturus, Life Technologies) were used to
ensure purity of all primary cancer epithelial cells and
omental metastatic cells. Approximately 30,000 cells
were collected for each of the 14 tissue samples (seven
primary and seven matched metastatic ovarian cancer
samples).15 Immune response_MIF-induced cell adhesion,
migration and angiogenesis
3.06E-07
16 Immune response_MIF - the neuroendocrine-
macrophage connector
3.06E-07
17 Development_TGF-beta-dependent induction of
EMT via SMADs
5.02E-07
18 Cell adhesion_Integrin-mediated cell adhesion and
migration
6.77E-07
19 Transport_Clathrin-coated vesicle cycle 7.47E-07
20 Cell adhesion_Role of tetraspanins in the integrin-
mediated cell adhesion
1.27E-06
Enriched pathways were computed utilizing the 3,365 significantly
differentiated expressed genes (4,389 probe sets) represented in the clustering
analysis (Figure 1). Thirteen of the 20 pathways (highlighted in bold) are
involved in EMT or EMT-related processes (iCe., cytoskeleton remodeling, cell
adhesion, EMT developmental processes, MIF-associated cell adhesion).RNA extraction and amplification
PicoPure RNA Isolation Kit (Life Technologies) proto-
cols were followed for RNA extraction from the cells on
the Macro-LCM caps in 30 μL of extraction buffer. RNA
quality was verified for all samples on the Bioanalyzer
RNA Pico Chip (Agilent Technologies). Total RNA from
the above extractions was processed using the Ovation®
Pico WTA System (NuGEN) in conjunction with the
Encore™ BiotinIL Module (NuGEN), to produce an amp-
lified, biotin-labeled cDNA suitable for hybridizing
to GeneChip Human Genome U133 Plus 2.0 Arrays
(Affymetrix) following manufacturer’s recommendations.Microarray data analysis
Fourteen individual gene expression profiles were gener-
ated from the primary and matched metastatic samples
of each of the seven patients used in this study. The 14
Affymetrix .CEL files were processed using the Affy-
metrix Expression Console (EC) Software Version 1.1
using the Robust Multi-Array Average (RMA) norma-
lization method. The normalized expression values from
all 14 samples were log2 transformed. From the initial
log2 transformed 54,675 probe sets (21,049 probe sets
transformed, unique, annotated genes), 50,286 that
displayed marginal differences in expression across all
patient samples (standard deviation ≤ 0.8 from the mean
of all 14 samples) were filtered out. The remaining 4,389
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vised clustering analysis.
For the identification of the epithelial to mesenchymal
transition (EMT) related genes, a list of 84 genes, previ-
ously implicated in the process of EMT, was employed
(http://www.sabiosciences.com/rt_pcr_product/HTML/PA
HS-090Z.html). Of these genes, 39 (61 probe sets) were
identified among the 3,365 genes (4,389 probe sets) differ-
entially expressed across samples.
Individual clustering analyses were carried out for
matched sets of primary and metastatic samples from
the Group 1 and Group 2 patients. All hierarchical clus-
tering was performed using normalized Z-scores of the
log2 transformed expression values.
Functional pathway enrichment
Biological interpretations of the differential gene expres-
sion data were performed by pathway enrichment ana-
lysis using MetaCore 5.2 (GeneGO, St Joseph, MI,
http://thomsonreuters.com/metacore/).
Results and discussion
Fourteen matched sets of primary and metastatic (omen-
tal) samples were collected from seven advanced staged
(III/IV) ovarian cancer (serous adenocarcinoma) patients.Figure 2 Comparative ranking of EMT-associated genes with respect
and Group 2 primary and metastatic samples. Thirty-nine previously ch
genes significantly differentially expressed across 14 tissue samples (see Fig
between primary and metastatic samples of Group 1 (panel a) and Group
differentially expressed between primary and metastatic samples from Grou
differences for some EMT-associated genes. These findings suggest that th
the primary and metastatic samples of Group 1 vs. Group 2 patients repres
occurrence in one and absence in the other.Pathological examination classified all of the cancer sam-
ples as highly un-differentiated with no significant differ-
ence in morphology between any of the primary and
metastatic sets (Additional file 1). Tissue samples for mo-
lecular analysis were snap frozen in liquid nitrogen within
one minute of surgical removal and subsequently embed-
ded in cryomatrix (Shandon) for frozen sectioning and
laser capture microdissection (LCM). Approximately
30,000 cancer epithelial cells were isolated from each tis-
sue sample and RNA was extracted and processed for
gene expression analysis (Affymetrix, U133Plus 2.0 arrays)
according to previously described methods [13].
Analysis of expression profiles for the 14 primary and
metastatic samples identified 3,365 genes (4,389 probe
sets) as being significantly differentially expressed
(Additional file 2). Unsupervised hierarchical clustering
of these data revealed that the metastatic samples of five
of the seven patients grouped closely with their respect-
ive primary samples (Figure 1a, b, Group 1). In contrast,
the metastatic samples from two of the patients (489 M
and 528 M) clustered most closely with one another and
distant from their respective primary samples (Figure 1a,
c, Group 2). Functional pathway analysis was carried out
incorporating the 3,365 differentially expressed genes de-
scribed above. The results indicated that 13 of the 20to fold-change differences in expression between the Group 1
aracterized EMT associated genes were identified among the 3,365
ure 1). Histograms depict the fold change differences in expression
2 (panel b) patients. Although EMT-associated genes are more
p 2 than Group 1 patients, Group 1 patients also display large fold
e observed differences in expression of EMT-associated genes between
ent differences in a continuum of the EMT-MET process rather than its
Lili et al. Journal of Ovarian Research 2013, 6:49 Page 5 of 7
http://www.ovarianresearch.com/content/6/1/49most significantly enriched pathways are associated with
EMT or EMT-related functions (i.e., cytoskeleton re-
modeling, cell adhesion, etc., Table 1).
To explore the possibility that differences in the ex-
pression of EMT-associated genes may contribute to the
dichotomy between Group 2 primary and metastatic
samples, we conducted additional analyses focusing on
genes previously established to be directly or indirectly
involved in the EMT process (Additional file 3). Thirty-
nine of these EMT-associated genes (61 probe sets) are
among the 3,365 genes (4,389 probe sets) used in our
clustering analysis (Figure 1). Figure 2 presents a com-
parative ranking of these 39 EMT-associated genes with
respect to fold-change differences in expression between
the Group 1 and Group 2 primary and metastatic sam-
ples. Nearly 74% (45/61) of the EMT-associated probe
sets display a > 2-fold change in expression in the Group
2 metastatic samples while only 18% (11/61) display a >Figure 3 Unsupervised classification of 39 differentially expressed EM
divergence between most primary and metastatic samples. Unsupervi
expressed across all samples demonstrates that the primary and metastatic
another. Primary and metastatic samples of all other patients cluster away
metastatic samples have undergone EMT while displaying a range of partia
metastatic site. The alternative hypothesis that metastasis occurs in the abs
only one Group 1 patient (620).2-fold difference in expression in the Group 1 metastatic
samples. In addition, a number of the differences in ex-
pression are consistent with the hypothesis that, on the
molecular level, Group 2 metastatic samples are more
mesenchymal-like than their matched primary samples.
For example, the expression of several “mesenchymal
biomarkers”, i.e., VIM (vimentin), TMEFF1 (transmem-
brane protein with EGF-like and two follistatin-like
domains 1), ITGAV (integrin alpha-V), and ZEB1 (zinc
finger E-box-binding homeobox1) are all up regulated
(2 to 3-fold) in Group 2 metastatic samples while being
essentially unchanged between Group 1 primary and
metastatic samples. However, a number of other genes
typically up-regulated during EMT [e.g., COL3A1 (colla-
gen type III alpha-1), FN1 (fibronectin), VCAN (vesican),
and MMP2 (matrix metalloproteinase-2] were not only
up-regulated in Group 2 metastatic samples but in
Group 1 metastatic samples as well, albeit at generallyT associated genes (61 probe sets) demonstrates significant
sed hierarchical clustering of EMT associated genes differentially
samples of only one patient (620) are clustered most closely with one
from one another consistent with a model whereby all of the
l or complete (patient 620) compensating MET transitions at the
ence of EMT is definitively consistent with the molecular profiles of
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differences in expression of EMT-associated genes be-
tween the primary and metastatic samples of Group 1
vs. Group 2 patients represent differences in a con-
tinuum of the EMT-MET process rather than its occur-
rence in one and absence in the other.
To explore this possibility further, we conducted a sec-
ond clustering analysis using only genes previously impli-
cated in EMT (Additional file 3). The results (Additional
file 4) presented in Figure 3 demonstrate that with respect
to these EMT-associated genes, the primary sample of
only one patient (620) remained most closely clustered
with its metastatic counterpart. The primary and meta-
static samples of all of the remaining patients displayed
various degrees of isolation from one another. Collectively,
our results are consistent with a model whereby all of the
metastatic samples have undergone EMT while displaying
a range of partial or complete (patient 620) compensating
MET transitions at the metastatic site. The alternative hy-
pothesis that metastasis occurs in the absence of EMT is
definitively consistent with the molecular profiles of only
one Group 1 patient (620).
The majority of cancer-related deaths are attributable to
metastases rather than to primary tumors [14]. For this
reason, there is considerable interest in understanding the
molecular mechanisms underlying the process with the
hope that such knowledge may lead to more effective
therapeutic treatments [11]. Considerable evidence has ac-
cumulated in recent years from innumerable in vitro and
animal model studies e.g., [5-8] indicating that EMT is
playing a key role in the metastatic spread of cancer cells
from primary sites. Despite the significant body of support
for this model, the lack of definitive clinical evidence in
human cancer patients has resulted in persistent and spir-
ited skepticism [9,10]. Much of this skepticism is based
upon the fact that human metastatic samples consistently
display morphologies indistinguishable from the primary
tumors from which they are derived.
In an effort to help resolve this controversy, we
conducted morphological and molecular analyses of 14
matched sets of primary and metastatic samples from
late staged (III/IV) ovarian cancer patients. Pathological
examination revealed no morphological differences be-
tween any of the primary and metastatic samples. In
contrast, gene expression analyses identified two distinct
groups of patient samples. In one group, the molecular
profiles of primary and metastatic samples from the
same patient displayed indistinguishable molecular pro-
files. While this result is not inconsistent with an EMT
model where mesenchymal-like metastasizing cells have
undergone a compensating MET transition at the meta-
static site, the results are equally consistent with the hy-
pothesis that metastasis in these patients did not involve
EMT. However, molecular profiling also identified asecond group of patient samples where the metastatic
samples from different patients clustered together and
were clearly distinct from their respective primary sam-
ples. Further analyses demonstrated that differences in
the expression patterns of genes previously associated
with EMT clearly separated the primary and metastatic
samples isolated from all but one patient.
Conclusions
Collectively, our results support a role of EMT in ovar-
ian cancer metastases and demonstrate that indistin-
guishable morphologies between primary and metastatic
cancer samples is not sufficient evidence to negate the
role of EMT in the metastatic process.
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